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ABSTRACT
Background
Celiac disease is a small intestinal inflammatory disorder characterized by malabsorption,
nutrient deficiency, and a range of clinical manifestations. It is caused by an inappropriate
immune response to dietary gluten and is treated with a gluten-free diet. Recent feeding
studies have indicated oats to be safe for celiac disease patients, and oats are now often
included in the celiac disease diet. This study aimed to investigate whether oat intolerance
exists in celiac disease and to characterize the cells and processes underlying this intolerance.
Methods and Findings
We selected for study nine adults with celiac disease who had a history of oats exposure.
Four of the patients had clinical symptoms on an oats-containing diet, and three of these four
patients had intestinal inflammation typical of celiac disease at the time of oats exposure. We
established oats-avenin-specific and -reactive intestinal T-cell lines from these three patients, as
well as from two other patients who appeared to tolerate oats. The avenin-reactive T-cell lines
recognized avenin peptides in the context of HLA-DQ2. These peptides have sequences rich in
proline and glutamine residues closely resembling wheat gluten epitopes. Deamidation
(glutamine!glutamic acid conversion) by tissue transglutaminase was involved in the avenin
epitope formation.
Conclusions
We conclude that some celiac disease patients have avenin-reactive mucosal T-cells that can
cause mucosal inflammation. Oat intolerance may be a reason for villous atrophy and
inflammation in patients with celiac disease who are eating oats but otherwise are adhering to
a strict gluten-free diet. Clinical follow-up of celiac disease patients eating oats is advisable.
Introduction
Celiac disease is a chronic inﬂammatory condition caused by an inappropriate immune
response of intestinal T-cells reactive to gluten proteins of wheat and similar prolamin proteins
of related cereals [1]. The majority of the peptides recognized by intestinal T-cells are more
immunogenic following deamidation by tissue transglutaminase (TG2). These peptides are
invariably presented by HLA-DQ2 or -DQ8, the same HLA molecules that confer genetic
predisposition to celiac disease [1]. Gluten-reactive intestinal T-cells can be isolated from
virtually all patients with celiac disease but not from normal individuals. The disease goes into
remission when harmful cereals are avoided. A gluten-free diet is thus the standard treatment of
this disorder.
Oats have traditionally been excluded from the gluten-free diet. Several feeding studies,
however, have indicated that patients with celiac disease and dermatitis herpetiformis tolerate
oats without signs of intestinal inﬂammation [2–9]. Of note, some of these studies have high
patient-dropout rates that may have masked cases of oat intolerance. An in vitro study found no
signs of T-cell activation in small intestinal biopsies of celiac disease patients challenged with
avenin (the prolamin fraction of oats) [10], and avenins have been predicted to contain only a
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making avenins less immunogenic [11,12]. On this basis, oats
have been allowed in the gluten-free diet in several countries
[13].
It remains to be proven that all celiac disease patients
tolerate oats following long-term exposure. A recent study of
39 Finnish patients randomized to eat a gluten-free diet with
50 g of oats daily or a standard gluten-free diet for 1 y
reported more intestinal symptoms and more gut inﬂamma-
tion in the group of patients eating oats, although the
mucosal integrity was not disturbed [14]. In an open challenge
study of 19 adult celiac disease patients using pure oats, one
patient developed villous atrophy [15]. This ﬁnding prompted
us to investigate the phenomenon of oat intolerance further
in a selected series of nine adult celiac disease patients, three
of whom had clinical oat intolerance. The goal of the study
was to characterize the intestinal T-cell response to oats
avenin proteins in these patients in detail and to relate this to
clinical symptoms and intestinal biopsy ﬁndings.
Methods
Participants
We studied nine adults with celiac disease who had a
history of exposure to pure oats. The oats were derived from
a quality-controlled production line and were shown to be
free from contamination of other cereals as described
elsewhere [15]. The selection of the study participants was
not random. Five of the patients (CD359, CD377, CD422,
CD431, and CD482) participated in a clinical challenge study
consisting of 19 adults with celiac disease who ate 50 g oats
daily for 12 wk [15]. One of these patients (CD422) has
symptoms and mucosal inﬂammation on oats consumption as
described [15]. Patient CD431 has slight mucosal inﬂamma-
tion when eating oats but is clinically well. The three
remaining individuals eat and tolerate oats. All these ﬁve
patients agreed to undergo gastroduodenoscopy for research
purposes. In addition, two other adults with celiac disease
(CD446 and CD504) were recruited from our ordinary
outpatient clinic. Patient CD446 eats and tolerates oats,
whereas patient CD504 has anaphylactoid symptoms after
intake of oats but has no mucosal inﬂammation. Finally, two
patients (CD496 and CD507) were referred by a general
practitioner and a referring hospital for investigation of
complications arising when eating a gluten-free diet, here
termed complicated celiac disease. The latter four patients
came for gastroduodenoscopy for clinical reasons, and agreed
to have extra biopsies taken for research purposes. We were
unable to measure serological parameters in these last four
patients because no serum samples were taken from them
during their clinical course. The study was approved by the
regional ethical committee. The participants gave their
informed consent.
Histopathological Assessment
We took small intestinal biopsies from the horizontal part
of the duodenum by gastroduodenoscopy using an Olympus
(Tokyo, Japan) GIF-IT140 scope and scored them according
to the modiﬁed Marsh criteria [16]. Intraepithelial lympho-
cytes were counted in hematoxilin-eosin-stained sections and
enumerated per 100 enterocytes. Five areas per biopsy were
counted, each encompassing 50–100 epithelial cells.
Grain Antigens and Peptides
Oat grains (Regal, Oslo, Norway) were ground and the ﬂour
was washed twice with water-saturated 1-butanol. The pellet
was dissolved in 45% ethanol overnight and centrifuged. The
avenin fraction was precipitated from the supernatant by
adding two volumes of 1.5 M NaCl. The precipitate was
dissolved either in 0.01 M acetic acid (pH 1.8) and digested
with pepsin and subsequently trypsin (pH 7.8) or in 2 M urea /
0.01 M NH4HCO3 and digested with chymotrypsin. Gluten
and gliadin (ethanol-soluble proteins of gluten) were isolated
from household wheat ﬂour and digested with chymotrypsin
as described [17].
Avenin peptides were synthesized on a robotic system (Syro
MultiSynTech, Bochum, Germany) using Fmoc/OtBu chem-
istry and 2-chlorotrityl resin (Senn Chemicals, Dielsdorf,
Switzerland). The identity of the peptides was conﬁrmed by
electrospray mass spectrometry, and purity was analyzed by
reverse-phase HPLC.
Treatment of the peptides with guinea pig (Sigma; St.
Table 1. Characteristics of the Included Patients
Patient Born Sex HLA-Type Clinical Symptoms
to Oats
Histology on
Oats-Containing Diet
Gluten-Reactive
T-Cell Lines
Avenin-Reactive
T-Cell Lines
DR DQ
CD496 1934 F 3, 7 2 Yes Marsh 3A Yes Yes
CD422 1961 F 3, 7 2 Yes Marsh 3B Yes Yes
CD507 1944 F 3, 7 2 Yes Marsh 3A Yes Yes
CD504 1963 F 7, 11 2, 3 Yes Marsh 0 Yes No
CD431 1970 F 3 2 No Marsh 1 Yes Yes
CD359 1951 F 2, 3 1, 2 No Marsh 1 Yes No
CD446 1954 F 3 2 No Marsh 2 Yes No
CD377 1949 M 3, 5 2, 3 No Marsh 0 Yes No
CD482 1949 F 1, 3 1, 2 No Marsh 0 Yes Yes
DOI: 10.1371/journal.pmed.0010005.t001
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Oat Intolerance in Celiac Disease PatientsFigure 1. Histology of Intestinal Mucosa of Two of the Oat-Intolerant Patients
Small intestinal biopsies were obtained at diagnosis, after an ordinary gluten-free diet (remission), after introduction of oats, and after
withdrawal of oats (recovery). For patient CD496, a biopsy was not taken after she started with a gluten-free diet. Biopsies were scored according
to the modiﬁed Marsh criteria. Hematoxilin-eosin staining was used, and IEL counts are given in the corners of the photomicrographs. The
remission biopsy from patient CD507 was poorly oriented. We therefore melted and reoriented this biopsy (insert). Original magniﬁcation:
1003.
DOI: 10.1371/journal.pmed.0010001.g001
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Oat Intolerance in Celiac Disease PatientsLouis, Missouri, United States) and human recombinant TG2
was performed in the presence of 1 and 2 mM CaCl2,
respectively, at 37 8C for 2 h.
T-Cell Assays
The generation of T-cell lines, T-cell cloning, and T-cell
proliferation assays were performed as described elsewhere
[17]. Single biopsy specimens from the patients were
challenged in vitro with either a pepsin-trypsin digest or a
chymotrypsin digest of avenin. As control, single biopsy
specimens were challenged with a chymotrypsin digest of
gluten or gliadin. DR3þDQ2þ B lymphoblastoid cells (irradi-
ated 80 Gy) were used as antigen-presenting cells. Positive T-
cell responses were deﬁned as a stimulatory index (SI) ([T þ
APCþantigen] divided by [TþAPC]) above 3. Determination
of HLA restriction of the T-cells was done by testing
inhibition of T-cell proliferation by the monoclonal anti-
bodies B8.11 (anti-DR), SPV-L3 (anti-DQ), 2.12.E11 (anti-
DQ2), and W6/32 (anti-HLA class I).
Purification of Avenin Fragments
A pepsin-trypsin digest of avenin was separated by gel
ﬁltration (FPLC, column Superdex Peptide HR 10/30;
Pharmacia Biotech, Uppsala, Sweden), and a fraction con-
taining T-cell stimulatory fragments was further separated by
reverse-phase HPLC (A ¨ kta, Pharmacia Biotech; column
Jupiter 5l C18, 250 3 4.6 mm, Phenomenex, Torrance,
California, United States) using an acetonitrile gradient from
5% to 40% with 1%/min and from 40% to 64% with 3%/min
(ﬂow rate 0.9 ml/min, containing 0.05% triﬂuoroacetic acid).
Mass Spectrometry and Database Searching
Electrospray ionization tandem mass spectrometry was
performed on a quadrupole time-of-ﬂight hybrid mass
spectrometer (Micromass, Manchester, England). For spray-
ing, needles were typically held at 900 V towards a skimmer
cone (40 V). In collision-induced dissociation of selected
peptide ions (collision gas argon; collision energy 25–35 eV),
the generated characteristic b- and y-type fragment ions [18]
were detected by the orthogonal TOF mass analyzer. All
tandem mass spectrometry spectra were centroided and
searched against in the NCBInr database via the Mascot
Search Engine (http://www.matrixscience.com).
Results
Clinical and Histological Characteristics
Nine adults with celiac disease who had a history of
exposure to oats assessed to be free from contamination of
other cereals were studied. In some cases they came for
gastroduodenoscopy for clinical reasons, in other cases, they
agreed to come for research reasons. The characteristics of
the patients are given in Table 1. This case series is thus not a
consecutive series of ordinary patients with celiac disease.
Three of these patients (CD422, CD496, and CD507) were
known to exhibit clinical and histopathological signs of oat
intolerance. Patient CD422 developed villous atrophy and
dermatitis while eating oats, and details of this patient are
described elsewhere [15]. Patient CD496 was a 53-y-old
woman who was evaluated for complicated celiac disease.
Celiac disease was diagnosed in 1987 after 1 y with diarrhea
and weight loss; a biopsy showed a Marsh 3C lesion with an
intraepithelial lymphocyte (IEL) count of 58/100 enterocytes
(range 53–69) (Figure 1). She responded well to a standard
gluten-free diet. A control biopsy was not taken. In 2001, she
started eating pure oats, but lost weight, going from 55 kg to
44 kg. While eating oats, a biopsy showed a Marsh 3A lesion
with an IEL count of 54/100 enterocytes (range 43–62). The
oats were discontinued, and she gradually recovered. Some
months later, an intestinal biopsy demonstrated a Marsh 1
lesion with an IEL count of 46 (range 28–52). Clinically she is
currently well. Patient CD507 was a 59-y-old woman who was
also evaluated for complicated celiac disease. She probably
had undiagnosed celiac disease since childhood and was
diagnosed in 1990 after osteoporotic fractures. A biopsy
showed total villous atrophy (Marsh 3C) with an IEL count of
50/100 enterocytes (range 44–54) (Figure 1). She responded
well to a standard gluten-free diet. In 1999, a follow-up biopsy
showed complete normalization of her mucosa (Marsh 0) with
an IEL count of 26/100 enterocytes (range 24–32). In 2000, the
patient started eating oats and developed bloating, abdomi-
nal pain and iron deﬁciency. She lost 2 kg in weight. In 2002,
while still eating oats, a biopsy showed a Marsh 3A lesion with
an IEL count of 50/100 enterocytes (range 38–58). She
discontinued eating oats and improved clinically. A new
biopsy later in 2002 showed improvement, with a Marsh 1
lesion with an IEL count 32/100 enterocytes (range 24–46).
Surprisingly, in late 2003 she was diagnosed with an
Table 2. T-Cell Responses to Avenin, Gluten, and Avenin Peptides in T-Cell Lines Established from Biopsies Stimulated with Avenin
Antigen
Avenin-Reactive T-Cell Line Avenin Gluten Peptide 1490 Peptide Av-a9B
 TG2 þTG2  TG2 þTG2  TG2 þTG2  TG2 þTG2
CD496.2.1 6.9 7.8 1.2 3.6 5.2 7.2 2.2 7.2
CD422.2.4 2.8 9.9 1.2 6.3 2.8 4.8 1.7 9.8
CD507.2.3 2.8 7.8 6.4 8.3 0.9 1.0 1.0 3.7
CD431.2.0 2.2 4.5 0.9 1.1 1.0 5.4 0.9 0.9
CD482.2.1 7.7 7.8 1.2 1.4 1.1 1.3 1.1 1.4
Both untreated and TG2-treated antigens were tested for recognition. The protein antigens were tested at 100 lg/ml, and the peptide antigens were tested at 10 lM. The
responses are given as SIs ([T þ APC þ antigen] divided by [T þ APC]), and positive responses are indicated by bold type.
DOI: 10.1371/journal.pmed.0010005.t002
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Oat Intolerance in Celiac Disease PatientsFigure 2. Identification of an Epitope in Avenin Recognized by Intestinal T-Cells of Celiac Disease Patients
(A) Reverse-phase HPLC of a pepsin-trypsin digest of avenin. Peptides in fraction 25, obtained from gel ﬁltration, were eluted by an acetonitrile
gradient (straight line), and 41 fractions were collected. Fractions recognized by T-cell lines in subsequent experiments are indicated by the
numbers above the peaks.
(B) T-cell recognition of fractions obtained by reverse-phase HPLC. All 41 fractions obtained in (A) were tested for recognition by the intestinal
T-cell line 422.2.4 (derived from an oat-intolerant celiac disease patient). The fractions were incubated with DR3-DQ2 homozygous antigen-
presenting cells overnight before the T-cell line was added. Speciﬁc T-cell responses were measured by
3H-thymidine incorporation. Pepsin-
trypsin-digested avenins, both TG2-treated and untreated, were used as control antigens.
(C) Sequences of the peptides in the stimulatory fractions from reverse-phase HPLC identiﬁed by tandem mass spectrometry and overlapping
synthetic peptides used for T-cell assays. For better comparison, the amino acid sequence of the avenin precursor protein JQ1047 (gi82331) is
taken as a consensus sequence, and deviating residues are underlined.
DOI: 10.1371/journal.pmed.0010002.g002
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Oat Intolerance in Celiac Disease Patientsadenocarcinoma in the small intestine, which was removed
surgically.
Avenin-Reactive T-Cell Lines Generated from Intestinal
Biopsies Challenged with Avenin
Responses to TG2-treated avenin were detected in the
polyclonal T-cell lines derived from the avenin-challenged
biopsies from all three patients who had clinical and
histopathological signs of oat intolerance (Table 1). Intestinal
T-cell responses to TG2-treated avenin were also found in
two of the other six patients. At least one avenin-reactive T-
cell line from each patient was expanded. Inhibition experi-
ments using anti-HLA class I and class II monoclonal
antibodies demonstrated that these T-cell lines were all
restricted to DQ2 (Figure 3; unpublished data), and with the
exception of the T-cell line generated from patient CD482,
they all gave an enhanced T-cell response to avenin treated
with TG2 compared to avenin not treated with TG2 (Table 2).
T-cell lines derived from the biopsies challenged ex vivo with
avenin gave higher responses to the TG2-treated avenin than
to TG2-treated gluten in four of ﬁve patients (CD422, CD431,
CD482, and CD496, but not CD507; Table 2). Notably,
intestinal T-cells speciﬁc for TG2-treated wheat gluten and
gliadin were identiﬁed in control biopsies challenged with
gluten in all nine celiac patients (see Table 1).
Identification of a T-Cell Epitope in Avenin
To identify the T-cell stimulatory peptides, we initially
studied an avenin-speciﬁc T-cell line (TCL CD422.2.4)
isolated from the oat-intolerant patient CD422. The T-cells
weakly recognized one gel ﬁltration fraction (#25) of a
pepsin-trypsin digest of avenin. This fraction was further
separated by reverse-phase HPLC, and retested for T-cell
recognition (Figure 2A and 2B). Stimulatory fractions were
subjected to electrospray ionization tandem mass spectrom-
etry (Figure 2C). For fractions 3 and 4, a single 22-mer
peptide was identiﬁed differing only by an asparagine
(fraction 3) and an aspartic acid residue (fraction 4). The
two identiﬁed peptides from fraction 8 represent C-termi-
nally elongated derivates of these 22-mers. Five peptides
identiﬁed from fraction 9 correspond to N-terminally
truncated and C-terminally elongated variants.
T-Cell Recognition of Synthetic Avenin Peptides
Four avenin peptides (1488, 1489, 1490, and 1491; Figure
2C) almost completely covering the sequences identiﬁed in
the reverse-phase HPLC fractions 3, 4, 8, and 9 were
synthesized and tested for T-cell recognition. Only peptide
1490 (SEQYQPYPEQQEPFVQQQQ) was recognized by the T-
cell lines CD422.2.4, CD496.2.1, and CD431.2 (see Table 2;
Figure 3). The recognition of this peptide by the T-cell lines
CD422.2.4 and CD431.2 was dependent on TG2 treatment. T-
cell line CD496.2.1 responded to the native peptide, but the
response was augmented by treatment with TG2. We
identiﬁed one deamidation site by tandem mass spectrometry
(underlined in the above given sequence). This regioselectiv-
ity of deamidation conforms to the previously deﬁned
speciﬁcity of TG2 [11,19]. Several truncation variants of
peptide 1490 were also synthesized. The shortest peptides
tested were 12-mers; the T-cell line CD431.2 recognized
peptide 1505 (YQPYPEQQEPFV) after TG2 treatment and
the already deamidated peptide 1504 (YQPYPEQEEPFV)
without TG2 treatment (Figure 3). We predict the 9-mer
core region binding to DQ2 as PYPEQEEPF, placing the
glutamic acid resulting from the deamidation at the P6
position. This is similar to the DQ2-a-I gliadin epitope
(PFPQPELPY), which also binds to DQ2 with a glutamic acid
at the P6 position [20,21]. Recently, Vader et al. studied
whether T-cells generated from celiac disease biopsies
stimulated with wheat gluten would cross-react with pre-
dicted epitopes of barley, rye, and oats. From these studies
they found two broadly reactive polyclonal T-cell lines that
responded to peptides from barley hordeins, rye secalins, and
the avenin-derived peptides Av-a9A, which is identical to a
length variant of 1490 (QYQPYPEQQEPFVQ), and Av-a9B
(QYQPYPEQQQPFVQ) [22]. We tested peptide Av-a9B
against our T-cell lines and found that it was recognized by
T-cell lines from the patients CD422 (line 2.4), CD496 (lines
Figure 3. HLA Restriction and Avenin Peptide Specificity of the Intestinal T-Cell Line 431.2 from Patient CD431
The avenin antigen (at 0.25 mg/ml) and peptides (at 10 lM), treated with TG2 when indicated, were incubated overnight with DR3-DQ2
homozygous antigen-presenting cells before T-cells were added. In the HLA restriction experiments, anti-DR or anti-DQ monoclonal antibodies
were added 30 min prior to the T-cells. T-cell responses were measured by
3H-thymidine incorporation and are represented as SIs.
DOI: 10.1371/journal.pmed.0010003.g003
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Oat Intolerance in Celiac Disease Patients2.1 and 2.3), and CD507 (line 2.3) after TG2 treatment (Table
2; unpublished data). From the T-cell line CD496.2.3, we
generated a T-cell clone that was speciﬁc for the peptide Av-
a9B after TG2 treatment (Figure 4A). This clone responded
also to TG2-treated avenin, but did not display cross-
reactivity to TG2-treated gluten nor to the TG2-treated
1490 peptide (Figure 4B). The avenin-reactive T-cell line
generated from the patient CD482 (CD482.2.1) did not
recognize the 1490 peptide nor the Av-a9B peptide. Thus,
there exist at least two distinct peptides of oats that can elicit
mucosal T-cell responses in celiac disease patients with
clinical intolerance to oats.
Location of Epitopes to a Proline- and Glutamine-Rich
Region of Avenin
The avenin epitopes we identiﬁed are localized to a region
of avenin uniquely rich in proline and glutamine residues
(Figure 5). The presumed 9-mer core region of the avenin
epitopes (PYPEQQEPF and PYPEQQQPF) contains three
proline residues. The high number of proline residues and
the localization of the epitopes to a region rich in proline and
glutamine residues bear strong resemblance to features
typical of DQ2-restricted T-cell epitopes of wheat gliadin
[23,24].
Discussion
A number of previous reports concluded that all celiac
disease patients tolerate oats. These reports have formed the
basis for approving oats in the gluten-free diet for the
treatment of celiac disease. The ﬁndings reported here
demonstrate that oat intolerance exists in some celiac disease
patients, and the study provides a molecular explanation for
this intolerance.
Oats are less related to wheat than are barley and rye. In
oats, the prolamines represent much less of the total seed
proteins than in the other cereals [25]. In addition, avenins
contain about half the amount of proline residues (10%) as
the prolamins of wheat (gliadins and glutenins), barley
(hordeins), and rye (secalines). On this basis, it is intriguing
that the identiﬁed avenin epitopes are located in the regions
of avenins with the highest content of proline residues,
regions also rich in glutamine. This is analogous to the
localization of the T-cell epitopes in a- and c-gliadins [23].
Figure 4. Reactivity of an HLA-DQ2-Restricted T-Cell Clone Derived from
a T-Cell Line (CD496.2.3) Established by Avenin Stimulation of an
Intestinal Biopsy of Patient CD496
T-cell responses were measured by
3H-thymidine incorporation and
are represented as SIs.
(A) The clone speciﬁcally recognizes the avenin peptide Av-a9B after
treatment with TG2. The peptides were tested at 10 lM.
(B) The clone recognizes avenin but not gluten antigen after
treatment with TG2.
DOI: 10.1371/journal.pmed.0010004.g004
Figure 5. Amino Acid Sequence of an Avenin (gi 82331, JQ1047) and an a-Gliadin (a2-Gliadin, AJ133612)
The proline and glutamine residues are red and blue, respectively. In the avenin, the presumed 9-mer core region of the characterized T-cell
epitope is underlined. In the a-gliadin, a 33-mer natural fragment containing six copies of three partly overlapping epitopes (DQ2-a-I,
PFPQPQLPY; DQ2-a-II, PQPQLPYPQ; and DQ2-a-III, PYPQPQLPY) is underlined. Note the localization of all the epitopes to regions of the
proteins rich in proline and glutamine residues and the high number of proline residues within the 9-mer core regions of the epitopes.
DOI: 10.1371/journal.pmed.0010005.g005
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Oat Intolerance in Celiac Disease PatientsThe immunogenicity of gliadin peptides is inﬂuenced both by
the glutamine residues, which become speciﬁcally deami-
dated by TG2, and by the proline residues, which protect the
peptides from proteolysis in the gastrointestinal tract,
determine the speciﬁcity of TG2, and are crucial for the
selective binding to HLA-DQ2 [1]. This study shows that the
same features apply to T-cell epitopes of avenin.
In humans it is impossible to directly demonstrate that T-
cells induce disease. In celiac disease this relates equally to T-
cells reactive to gluten and to T-cells reactive to avenin. The
fact that avenin-reactive intestinal T-cells, like gluten-reactive
T-cells from celiac disease patients, are uniquely restricted by
HLA-DQ2 and are activated by TG2-treated peptides speaks
strongly in favor of their involvement in the disease patho-
genesis. The ﬁnding of avenin-speciﬁc intestinal T-cells also
in individuals with celiac disease that are clinically tolerant to
oats does not, as we see it, contradict this assumption. Some
patients with celiac disease stay in remission for extended
time periods during gluten challenge even if it is likely that
they have gluten-reactive T-cells in their intestinal mucosa.
Since avenin is less immunogenic than wheat gluten, one
would expect an extended time for relapse to be at least as
common during oats consumption.
It is highly unlikely that the intolerance and the mucosal
inﬂammation observed in our patients could be explained by
contamination of the oat ﬂour by wheat, barley, or rye
proteins. All the oats consumed were produced in a quality-
assessed production line. Our data indicate that avenin can
drive mucosal inﬂammation in that the incubation of the
intestinal biopsies with avenin enriches for activated, avenin-
reactive T-cells. A substantial proportion of the avenin-
reactive T-cells appear to be speciﬁc to avenin. The T-cell
clone we established from an avenin-challenged biopsy was
reactive to avenin but did not cross-react to wheat gluten, and
the T-cell lines from biopsies challenged with avenin
responded more strongly to avenin than to gluten in four
of ﬁve participants. Cross-reactivity at the T-cell clonal level
has been demonstrated between wheat gluten, hordein, and
secalin antigens [22,26] and likely also exists between gluten
and avenin [22]. Even if some of the avenin-reactive T-cells
were originally primed to gluten and responded to avenin
because of cross-reactivity, they would still participate in an
avenin-driven immune response.
T-cell reponses to the avenin epitopes described in this
paper have been found in T-cell lines derived from intestinal
biopsies of patients with celiac disease that were stimulated
with gliadin [22]. It is unknown whether any of the patients
from whom these T-cells were isolated had clinical symptoms
or mucosal inﬂammation related to oats ingestion. Thus, to
our knowledge, the current study is the ﬁrst to demonstrate a
mechanistic link between clinical symptoms of oat intoler-
ance, mucosal inﬂammation, and avenin-reactive T-cells.
Oat intolerance can cause complications in the large group
of celiac disease patients who are now regularly consuming
oats. At this stage we do not know how frequently such
complications may occur. Presumably such complications will
not be very common, but only extended clinical follow-up of
oats-consuming celiac disease patients will establish the
frequency. Monitoring of T-cell responses to avenin epitopes
may potentially identify individuals who are at risk of
developing oat intolerance. Based on our data, such
monitoring will also identify some individuals who are
clinically tolerant to oats and who have minimal or no
mucosal pathology after a limited oats challenge. Possibly
some of these patients may have latent oat intolerance that
will develop into overt disease after prolonged exposure, but
this remains speculative. Our observations demonstrate that
even if oats seem to be well tolerated by many celiac disease
patients, there are patients who have an intestinal T-cell
response to oats. Until the prevalence of oat intolerance in
celiac disease patients is established, clinical follow-up of
celiac disease patients eating oats is advisable. Clinicians
should be aware that oat intolerance may be a reason for
villous atrophy and inﬂammation in patients with celiac
disease who are eating oats but otherwise are adhering to a
strict gluten-free diet.
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Patient Summary
Background. Celiac disease is a digestive disease that damages part of
the gut (the small intestine) and interferes with absorption of nutrients
from food. Patients with celiac disease do not tolerate a protein called
gluten, which is found in wheat, rye, and barley. When people with celiac
disease eat foods containing gluten, their immune system responds by
damaging the small intestine. The disease is quite serious in some
patients, but eating a strictly gluten-free diet can eliminate all of the
symptoms. Unfortunately, wheat, barley, and rye products like flour are
found in many common foods, and patients have to avoid them for the
rest of their lives. Previous studies suggested that oats were safe for
patients with celiac disease, and as a result, they often form part of a
gluten-free diet.
What Did the Researchers Find? Contrary to other studies, this one
demonstrates that oats intolerance does exist in some patients with
celiac disease. These patients have an immune reaction to oats that is
similar to the reaction most celiac disease patients have to wheat, barley,
and rye.
What Does This Mean for Patients? It appears that oats are not safe for
all patients with celiac disease. Patients who eat oats as part of a gluten-
free diet should discuss their diet and any symptoms with their doctors;
doctors should keep in mind that patients might develop symptoms
when they eat oats.
What Are the Problems with the Study? The researchers studied only a
small number of patients, and this study cannot tell us how common
oats intolerance is among celiac disease patients.
Where Can I Find More Information? US National Institutes of Diabetes,
Digestive,andKidneyDisorders:http://digestive.niddk.nih.gov/ddiseases/
pubs/celiac/
Celiac Disease Foundation: http://www.celiac.org/
The Gluten Intolerance Group: http://www.gluten.net/
The Celiac Disease Foundation: http://www.celiac.com/
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